0RCQ.LSE NicOx S.A.
- Market cap
- EUR 11.6M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2021.
Is 0RCQ.LSE undervalued?
Graham numberThe Graham number of NicOx S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NicOx S.A. fundamental analysis
No fundamental analysis for NicOx S.A. yet.
NicOx S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NicOx S.A.
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatme…
Full company profileNicOx S.A. financial statements
NicOx S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 16.0K | 2.31M | 4.03M | 6.86M | 12.9M | - |
| Gross Profit | 16.0K | - | - | - | - | - |
| Operating Income | -7.78M | -18.5M | -20.7M | -18.3M | -6.76M | - |
| Net Income | -19.0M | -3.62M | -18.4M | -18.9M | -18.1M | - |
| Balance Sheet | ||||||
| Total Assets | 149M | 151M | 139M | 143M | 142M | - |
| Total Liabilities | 44.2M | 24.0M | 24.9M | 33.5M | 41.5M | - |
| Shareholders' Equity | 105M | 127M | 114M | 109M | 101M | - |
| Cash & Short-term Investments | 28.9M | 41.4M | 22.1M | 28.1M | 47.2M | - |
| Total Debt | 30.0K | 26.0K | 54.0K | 10.2M | 13.4M | - |
| Cash Flow | ||||||
| Operating Cash Flow | -25.7M | -12.4M | -19.1M | -16.1M | -5.39M | -18.5M |
| Capital Expenditure | 124K | 77.0K | 228K | 63.0K | 20.0K | 8.00K |
| Ratios | ||||||
| ROE | -18.2% | -2.9% | -16.2% | -17.3% | -18.0% | - |
| ROA | -12.8% | -2.4% | -13.3% | -13.3% | -12.7% | - |
| Net Profit Margin | -118,968.8% | -157.0% | -456.7% | -276.0% | -140.2% | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.09x | 0.13x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NicOx S.A. dividends
NicOx S.A. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.2:1 on Dec 3, 2015.
Who owns NicOx S.A.
- Insiders 5.06%
- Institutions 1.58%
- Public & others 93.36%
- Shares outstanding 29.6M
- Free float 85.1M
NicOx S.A. company profile
- Company name
- NicOx S.A.
- Ticker
- 0RCQ.LSE
- ISIN
- FR0013018124
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 10
- Fiscal year end
- December
- Address
- Sundesk Sophia Antipolis, Biot, France, 06410
- Phone
- 33 4 97 24 53 00
- Website
- nicox.com
About NicOx S.A.
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
NicOx S.A. management
6- Dr. Gavin M. SpencerCEO & Director · born 1969
- Ms. Sandrine GestinVice President of Finance & Human Resources · born 1967
- Dr. Ramesh KrishnamoorthySenior Director and Head of Late Stage CMC & Quality Control
- Dr. Jose BoyerConsultant
- Mr. Doug HubatschChief Scientific Advisor · born 1967
- Ms. Siobhan GarbuttVice President & Head of Clinical Development